Results 131 to 140 of about 6,309 (194)

Polineuropatia amiloidótica familiar. Mais um passo em direcção ao futuro. [PDF]

, 2013
Maria Helena Miranda Rodrigues
core  

Monitoring heart involvement in treated and untreated transthyretin amyloidosis. [PDF]

Heart Fail Rev
Sinigiani G, Milani P, De Michieli L, Sanna GD, Perlini S, Cipriani A, Palladini G.   +6 more
europepmc   +1 more source

Val50Ala variant of familial amyloid neuropathy – a rare case in the Czech Republic [PDF]

, 2015

core   +1 more source

The Tafamidis Drug Development Program

JACC: Basic to Translational Science, 2018
Mathew S. Maurer, Douglas L. Mann
openaire   +1 more source

Nonagenarian patients with ATTR cardiac amyloidosis: should they be treated with tafamidis? [PDF]

Eur Heart J
Jobbé-Duval A, Damy T, Broussier A.
europepmc   +1 more source

Tafamidis: a new treatment for ATTR cardiomyopathy [PDF]

Nature Reviews Cardiology, 2018
openaire   +2 more sources

Transthyretin Amyloid Cardiomyopathy: The Plot Thickens as Novel Therapies Emerge. [PDF]

US Cardiol
Dimza M, Vasilakis G, Grodin JL.
europepmc   +1 more source

Cardiac contractility modulation as a novel therapeutic approach in transthyretin amyloid cardiomyopathy to improve eligibility to stabilizer therapy: a case report. [PDF]

Eur Heart J Case Rep
Díaz Expósito A, Pérez Cabeza AI, Márquez Camas P, Robles Mezcua A, García Pinilla JM.   +4 more
europepmc   +1 more source

SGLT2 inhibitors in cardiac amyloidosis: mechanistic insights and clinical perspectives-a narrative review. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Özlek B, Tanik VO.
europepmc   +1 more source

Real-world treatment management in hereditary transthyretin amyloidosis - an experience report and proposal for therapy switch decision criteria. [PDF]

Neurol Res Pract
Dieu DC, Pernice HF, Muratovic H, Wetzel PJ, Barzen G, Wieder NW, Werhahn SM, Heidecker B, Spethmann S, Hahn K.   +9 more
europepmc   +1 more source